Our results showed that treatment with AntiOxCIN4 increased total SOD activity in fibroblasts from sPD patients as well as their controls (Fig. 9C), while only fibroblasts from sPD patients treated with AntiOxCIN4 showed decreased levels of SOD2 protein content (Fig. 9D and E). This evidence concerns the gene SOD1 and Platelet storage pool disease.